Agios Pharmaceuticals (AGIO) logo

Agios Pharmaceuticals (AGIO) stock

$31.59
-0.54%

Rare disease medicines, worth $1.9BSmall-cap biotech

Why is AGIO down?

Down 17% from Oct 28 to Nov 13 while the S&P 500 fell 2%.

  • Agios Pharmaceuticals fell 17% from Oct 28 to Nov 13. It fell 18% on Oct 30 alone.

Sources: Price history, Nov 13, 2026

Tell me next time AGIO moves

Free account, no card. An optional alert when AGIO moves or its score changes.Pro, 7 days free with a card. An optional alert when AGIO moves or its score changes.

Or see it live, free until tomorrow morning. No account.
1 more reason, free with an account →The other side, how the business stands, the timeline, and its peers, for Pro members.
Quality Score
2
Below Average
In its industry
#99of 270
Checks firing
3of 14
Transition
From 52-week high
-31.3%
under its best in a year

AGIO's Quality Score was unchanged on Fri, Nov 13, at 2.

Follow AGIO's trial news. Pro members can get an alert when Agios Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when AGIO files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“Data from this trial are expected in the second half of 2026.”Trial data · SEC filing · Jul 30
Cash$907M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30

Key facts on AGIO

Key facts on AGIO
Since its 2024 highDown 48% profit $673.7M → a $372.9M loss a year
Latest filing8-K, Nov 5 Reported its quarterly results
1 more reason behind AGIO's 2, free with an account →3 more reasons behind AGIO's 2, for Pro members.

AGIO in the news

What's next

Sat Dec 12: American Society of Hematology…Industry event · date confirmed.

Expected to report Thu Feb 18, before the open

After its last 4 reports it closed -0.5% on average, higher 2 of 4 times.

Cash$907M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30

AGIO catalysts

Coming up

14 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for AGIO, and how long its cash lasts

Next step the company has named

2H 2026“Data from this trial are expected in the second half of 2026.”Trial data · SEC filing · Jul 30

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
ENERGIZEKidsPhase 3 · Recruiting · 45 people · main data estimated Mar 2029 · NCT07517133

14 more trials, 2 more milestones and 23 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 10 quarters

$907M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Feb 12, 2026)

For Pro members: the amounts, and the share count against a year ago.

Insiders

Chief Medical Officer Sarah Gheuens sold 7,866 shares on Oct 26, under a planned sale. 18 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Brian Goff’s 13 filings and quotes.

Get an alert when AGIO files news on its trialsA free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 150 dates, ranked →

Why AGIO scores 2

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

  • +3Chart checks 3 of 14 firing right now, one point each
  • +3Growth sales up 214% on the year, gross margin up 6.6 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Long-term trend subtracts
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Dilution, Persistence, and News.

What every line is worth, and the reason behind it, on AGIO and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 5:03 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How AGIO ranks in Biotech

AGIO is #99 of 270 by Quality Score.

How AGIO ranks in Biotech
RankStockQuality Score
99Agios Pharmaceuticals (AGIO) logoAGIOAgios Pharmaceuticals2

Share count against a year before: AGIO +2.7%, INO +89%, MLYS +26%, SVRA +17%.

More in Biotech

When does AGIO report earnings, and what happens after?

Expected to report Thu Feb 18, before the open (in 94 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What AGIO reported on Nov 5, 2026

The quarter

Sales of $55.4M, 330% more than a year ago; a loss of $1.09 a share, from $1.78.

“This growth was driven by the U.S. commercial launch of AQVESME in thalassemia, where broadening demand is translating into a durable base of patients on therapy,”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By region
United Statesup 296%$48.7M88%$40.9M91%$12.3M96%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

1 more line, for Pro members.

The outlook

No outlook figures read from this release.

In the company's words

  • “Research and Development (R&D) expenses were $73.5 million for the third quarter of 2026, compared to $86.8 million for the third quarter of 2025, driven primarily by reductions in spend associated with mitapivat and tebapivat process development and certain clinical trials.”

From its results filing (SEC filing · Nov 5)

1 more sentence, for Pro members.

The numbers

Market value
$1.9B
today
Sales
$141M
up 214% on the year
Free cash flow
-$336M
last 12 months

Its share count fell 3.4% a year over 5 years.

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on AGIO: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+13.1%-6.5%-9.9%
Apr 29Jul 30Nov 5
ReportedGapReaction5
days
Nov 5, 2026Before open-0.6%-9.9%+4.6%
Jul 30, 2026Before open-15.8%-6.5%-9.4%
Apr 29, 2026Before open+6.8%+13.1%+9.7%

AGIO closed higher after 2 of its last 4 reports.

All 4 reports, and AGIO's Quality Score going into each

AGIO sales and profit by year

Sales and profit by year

Sales grew in five of the last seven years, to $54M in 2025. It lost money in 2025 after a profit in 2024.

AGIO has 3 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on AGIO, and all 14 on every stock.Get in free →

AGIO RSI on Nov 13: 46.3, below its 50-day and 200-day averages

Not scored

RSI 46.3, MACD below signal, below both averages. Not scored.

The deep dive on AGIO

  • What it does and how it makes money3 findingsAn operating loss of $472M in fiscal 2025, on $54.0M of sales.Annual report, filed Feb 12, 2026
  • What changed in its filings5 findings"In June 2023, Merck filed a lawsuit against HHS and CMS asserting that, among other things, the IRA’s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution." (10-K for fiscal 2025)SEC filing · Feb 12, 2026A new heading in its "Risk Factors" this year: "Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development program and …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 12, 2026, against the one of Feb 13, 2025One customer made up 89% of its revenue in fiscal 2025, down from 95% in fiscal 2024.SEC filing · Feb 12, 2026
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades AGIO, for Pro members
  • Against its closest peers3 peersShare count against a year before: AGIO +2.7%, INO +89%, MLYS +26%, SVRA +17%.

6 more findings on AGIO, each with its source, for Pro members.

AGIO share count over time

3% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of AGIO outstanding, as filed
Shares
outstanding
As
of
59.8MOct 30, 2026
59.7MJul 24, 2026
59.5MApr 24, 2026
58.6MFeb 6, 2026
Offerings, shelves, and splits of AGIO, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3ASR)Feb 12, 2026

AGIO insider trades

No insider bought or sold AGIO in the last six months outside a trading plan. All 3 insider sales in the last three months were made under plans set up in advance, which the score leaves out.

AGIO trades by Congress and the executive branch

One trade disclosed in the last six months. The newest:

BuyGilbert Cisneros$1K to $15KHousetraded Aug 20, disclosed Sep 10(21 days later)

See what Congress is buying across the market

AGIO's officers and directors

Officers and directors with a Form 4 in the last 12 months.

8 more officers and directors file at AGIO.

See insider trades by person

Which ETFs hold AGIO?

In ETFs: AGIO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

540 employeesCambridge, MAagios.com

What Agios Pharmaceuticals says it competes with

“The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”

From its annual report, SEC filing · Feb 12, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on AGIO and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn AGIO's score around: 7 things
  • 3 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawaySep 10Gilbert Cisneros bought AGIO$1K to $15K, disclosed Sep 10

Alerts are optional.

See AGIO's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 16, 2026: AGIO's Quality Score is 2 (Below Average), #99 of 270 in Biotech.

What does AGIO's Quality Score say?

AGIO scores 2 today, which Breakaway calls Below Average. It is #99 of 270 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 17% from Oct 28 to Nov 13 while the S&P 500 fell 2%. Cash lasts about 10 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is AGIO's Quality Score?

AGIO scores 2 today, which Breakaway calls Below Average (0 to 5). That is #99 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AGIO's 2.

When does AGIO report earnings?

Expected to report Thu Feb 18, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. AGIO closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,145 stocks ranked

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for Agios Pharmaceuticals: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.